Is cardiac resynchronization therapy cost-effective?
Why the study?
Is cardiac resynchronization therapy (CRT-P and CRT-D) cost-effective in patients with heart failure and associated conduction disturbances?
Population
Patients with heart failure and associated conduction disturbances
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports modeling longer horizons for CRT cost-effectiveness; leaves open direct CRT-P versus CRT-D comparisons.
Key Points
- The research aims to evaluate the cost-effectiveness of cardiac resynchronization therapy (CRT) for heart failure patients.
- Analysis of cost-effectiveness and cost-utility estimates for CRT-P and CRT-D devices.
- Comparison of financial implications based on varying data sources and assumptions.
- Evaluation of time horizon effects on cost-effectiveness metrics.
- Cost-effectiveness estimates for CRT-P and CRT-D are below US$50,000 per quality-adjusted life-year.
- Longer time horizons improve perceived cost-utility of both device types.
- Insufficient data exist for direct comparison between CRT-P and CRT-D regarding cost-effectiveness.
Structured PICO
Is cardiac resynchronization therapy (CRT-P and CRT-D) cost-effective in patients with heart failure and associated conduction disturbances?
P
Population
Patients with heart failure and associated conduction disturbances
I
Intervention
Cardiac resynchronization therapy (CRT-P and CRT-D)
O
Outcome
Cost-effectiveness and cost-utility (cost per quality-adjusted life-year)
CRT-P and CRT-D appear to be cost-effective treatments for heart failure, generally falling below the $50,000 per QALY threshold, though estimates vary based on modeling assumptions.
Limitations
- Estimates are largely dependent on data source, assumptions, modelling technique, time horizon, and perspective
- Limited data on comparative cost-effectiveness of CRT-P vs CRT-D
- Need more data on real-world effectiveness and long-term benefits
Cite This Study
Boriani et al. (2009) studied this question.